ZIVO Zivo Bioscience, Inc.
Listings ·
The board says SEC reporting costs are no longer in the best interests of the company and its stockholders. ZIVO plans to file the form on or around March 30, 2026.
We have not published a story on Zivo Bioscience yet. When there is news, it will appear here.
Zivo Bioscience, Inc. is a research and development company operating in both the biotech and agtech sectors. Its intellectual property portfolio includes proprietary algal and bacterial strains, biologically active molecules, and production and cultivation techniques for human and animal health. Its therapeutic strategy develops bioactive extracts and molecules from its proprietary algal culture for diseases such as poultry coccidiosis, bovine mastitis, human cholesterol and canine osteoarthritis. Its lead candidate targets coccidiosis in broiler chickens and is described as a non-antibiotic immune modulator. In its nutrition business, the company sells a dried green algae powder with over 50% protein, produced at a site in Peru operated with Grupo Alimenta. Under a contract manufacturing arrangement, the company's ZIVOLife subsidiary commits to purchasing the entire output. Commercial shipments for human consumption began in June 2023 through a global distribution agreement. Full capacity at the Peru site is planned for 2027, with capability to produce roughly 100,000 kg per year.
| Product or program | What it is | Stage |
|---|---|---|
| Coccidiosis product candidate | Non-antibiotic immune modulator for coccidiosis in broiler chickens | |
| Dried green algae powder | Algae powder with over 50% protein for food or food ingredient use | Commercial shipments began June 2023 |
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $157,220 | $27,650 |
| Research and development | $3.1 million | $1.4 million |
| Net income (loss) | -$13.4 million | -$7.8 million |
| Cash from operations | -$4.3 million | -$5.8 million |
| Cash and equivalents | $1.5 million | $274,380 |
Our latest story on this, dated Mar 30, 2026: "ZIVO Bioscience to delist from OTC markets and file Form 15 to end SEC reporting". The story links the filing or release it is based on. Read the story.
Zivo Bioscience, Inc. trades under the ticker ZIVO on OTC.
Zivo Bioscience, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Zivo Bioscience, Inc. is 1101026. Its filings are on SEC EDGAR.
3,888,595 shares as of 2025-11-09, per the cover page of its 10-Q filed 2025-11-14.
Our directory records Zivo Bioscience, Inc. under United States.
Our directory classifies Zivo Bioscience, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Zivo Bioscience, Inc. is US98978N3098.
aibio.space lists Zivo Bioscience, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Zivo Bioscience, Inc. is a research and development company operating in both the biotech and agtech sectors. Its intellectual property portfolio includes proprietary algal and bacterial strains, biologically active molecules, and production and cultivation techniques for human and animal health.
Coccidiosis product candidate: Non-antibiotic immune modulator for coccidiosis in broiler chickens Stage: Stage not stated.
Dried green algae powder: Algae powder with over 50% protein for food or food ingredient use Stage: Commercial shipments began June 2023.
$157,220 for the fiscal year ended Dec 31, 2024, as reported to the SEC.
Zivo Bioscience, Inc. reported a net loss of $13.4 million for the fiscal year ended Dec 31, 2024, and used $4.3 million of cash in operations, per its annual report to the SEC.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio